Long-Term Care Pharmacies Say Negotiation Hurts Them Without PBM Reform
By Luke Zarzecki
Inside Health Policy
Long-term care pharmacies say the kick-off of Medicare drug price negotiation Tuesday (Aug. 29), while well-intentioned, will inadvertently hurt them and their patients unless policy makers also move forward on pharmacy benefit manager and Part D payment reforms.
“Long term care pharmacies are likely to be collateral damage,” Alan Rosenbloom, president and CEO of the Senior Care Pharmacy Coalition, told Inside Health Policy.
Eight of the 10 medications included on the Part D price negotiation list unveiled Tuesday are heavily prescribed to patients in long-term care facilities. Those pharmacies lose money on most of the medicine they prescribe and only make a profit on a small portion they fill, the coalition said.
Rosenbloom cheered on paying less for drugs both for consumers and the government, but said more action is needed. He said pharmacy benefit managers and insurance companies are primarily responsible for high drug costs and policy changes need to be enacted.
With the new drug negotiations, he said if PBMs and insurance companies don’t add alternatives to their formularies, that could make long-term care pharmacies “existentially threatened” and leave some people in long-term care facilities without medication.
That’s the worst-case scenario, he said. To avoid it, SCPC calls for federal regulators and lawmakers to act.
Read the full original article here.
Recent Posts
-
Senior Care Pharmacy Coalition Applauds Chairman Comer and House Oversight Committee for Shedding Light on Harmful PBM Practices, Encourages Congress to Advance PBM Reform Legislation Heard Today in House Energy and Commerce Committee Health Subcommittee
The Senior Care Pharmacy Coalition (SCPC), the leading national voice for the long-term care pharmacy community, released a statement today regarding the House Oversight Committee’s hearing on pharmacy benefit managers.
-
Stuck in the middle, LTC pharmacies could be dangerously squeezed by drug price negotiations
Any lower drug prices that result from White House efforts to negotiate on behalf of Medicare beneficiaries may lead to short-term gains for nursing homes, but there also could be a steep price to pay in the long-term, experts warned this week. The Centers for Medicare & Medicaid Services on Tuesday announced the first 10 drugs covered by Medicare Part D that will be included in negotiations running through 2024. They are all commonly prescribed drugs that treat conditions ranging from diabetes to arthritis and heart failure.
-
Biden’s Plans to Reduce Cost of Medicare Drugs To Send Ripple Effects Through Nursing Home Industry
Following the Biden Administration’s bid this week to reduce the price of certain drugs – many of which are commonly used in nursing homes – experts are cautioning that the changes may negatively impact the bottomline of organizations in the sector. As Medicare Part D price negotiations for these drugs come into focus this week, the Senior Care Pharmacy Coalition (SCPC), for one, is warning that changes to Part D might cause “collateral damage” to long-term care pharmacies, the patients they serve and operator partners.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.